The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
minimal risk level (MRL)
An ATSDR estimate of daily human exposure to a hazardous substance at
or below which that substance is unlikely to pose a measurable risk of
harmful (adverse), noncancerous effects. MRLs are calculated for a route
of exposure (inhalation or oral) over a specified time period (acute,
intermediate, or chronic). MRLs should not be used as predictors of harmful
(adverse) health effects [see reference dose].